EP3200829A1 - Verfahren zum konjugieren eines polypeptids - Google Patents

Verfahren zum konjugieren eines polypeptids

Info

Publication number
EP3200829A1
EP3200829A1 EP15782151.3A EP15782151A EP3200829A1 EP 3200829 A1 EP3200829 A1 EP 3200829A1 EP 15782151 A EP15782151 A EP 15782151A EP 3200829 A1 EP3200829 A1 EP 3200829A1
Authority
EP
European Patent Office
Prior art keywords
formula
group
maleimide
molecule
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15782151.3A
Other languages
English (en)
French (fr)
Other versions
EP3200829B1 (de
Inventor
Ronald James CHRISTIE
Changshou Gao
Nazzareno Dimasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP3200829A1 publication Critical patent/EP3200829A1/de
Application granted granted Critical
Publication of EP3200829B1 publication Critical patent/EP3200829B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Definitions

  • the present disclosure relates to a method of conjugating a polypeptide, such as a protein to a pay load, under conditions which do not damage the polypeptide to provide a stable molecule.
  • the disclosure also relates to molecules prepared or obtainable by the said methods and compositions comprising the same.
  • the disclosure further relates to use of the molecules prepared or obtained from the method in therapy, for example immunotherapy and/or cancer therapy.
  • PEG polyethylene glycol
  • the PEG has one of several functions in that it is thought to reduce immunogenicity of some molecules and/or increases the half-life of the molecules.
  • marketed therapies include: include: peginesatide, pegloticase, certolizumab pegol (Cimzia), Methoxy polyethylene glycol-epoetin beta (Mircera), pegaptanib (Macugen), pegfilgrastim (Neulasta), pegvisomant (Somavert), peginterferon alfa-2a (Pegasys),
  • Doxorubicin HC1 liposome Doxil/Caelyx
  • peginterferon alfa-2b Peglntron
  • pegaspargase Oncaspar
  • pegademase bovine Adagen
  • ADCs Antibody drug conjugates
  • ADCs are also an important category of therapeutic molecules. They are highly potent and similar to a "guided missile" in that an antibody component is conjugated to a payload, for example a cytotoxin, which is guided to the intended target by the antibody component.
  • ADCs include brentuximab vedotin and trastuzumab emtansine.
  • the linker formed in the conjugation chemistry is of vital importance in ADCs.
  • WO2013/173337 (Seattle Genetics Inc) which employs a maleimide derivative with an amine substituent at the position beta to the nitrogen in the maleimide ring.
  • the resultant succinimide can be hydrolysed under milder conditions.
  • the conjugation step is performed at a basic pH of about 8. The latter conditions can promote aggregation of proteinaceous materials, such as antibodies and antibody fragments, thereby causing loss of this precious material in the conjugation step.
  • the ratio of payload to antibody generally has to be increased to ensure all the antibody is conjugated.
  • the present disclosure provides methods employing mild conditions which provide molecules which are stable after preparation and therefore suitable for in vivo administration and in particular, which are suitable for use in therapy.
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p is 0 or 1 ;
  • q is 0 or an integer in the range 1 to 12, for example 1 to 6, such as 2 or 3;
  • Q is a bond or a residue from a conjugation component;
  • aryl or heteroaryl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C 1. alkyl, C 1.
  • Y is oxo
  • Z is a saturated or unsaturated branched or unbranched C 1.30 alkylene chain, wherein one or more carbons (such as 1, 2, 3, 4, 5, 6, 7 or 8) are optionally independently replaced by -0-, N and the chain is optionally bears one or more (such as 1, 2, 3 or 4) oxo substituents;
  • Rl is H, a solid surface or a payload molecule
  • R2 is a substituent, for example selected from H, halogen, hydroxyl, -C 1. alkyl, -Ci_6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF 3 , N0 2 , -S0 2 , -SO3, -NR 4 R5, -PO4, C6_io ArylCo-6 alkylene-, .10 memberedHeteroarylCo-6 alkylene-;
  • R 3 is H or Ci_6 alkyl
  • R 4 is H or C 1-6 alkyl
  • R5 is H or C I_ alkyl
  • the method includes a further step of hydrolysing the resultant thio-succinimide entity formed by the reaction of compound of formula (I) and the polypeptide, or c) wherein R1 is H the method comprises the further step of performing a conjugation with a payload or solid surface followed by hydrolysing the thio- succinimide entity formed by the reaction of compound of formula (I) and the polypeptide molecule.
  • the conjugates of the present disclosure can be prepared at acidic pHs such as about pH 5, and thio-succinimide hydrolysis can be performed under mild conditions.
  • the thio-succinimide in the conjugates can be rapidly hydrolysed under mild conditions.
  • the molecules of the present disclosure are stable in use, for example are stable in serum.
  • the aryl bears 1, 2, 3 or 4 fluoro substituents.
  • the disclosure herein also extends to a compound/product obtained or obtainable from said method, for example a product obtained after conjugation or a product obtained after hydrolysis of the succinimide.
  • a compound disclosed herein for example of formula (I), (II), (Ila), (Ilaa), (Ilaa'), (Ilaaa), (lib), (Ilbb), (Ilbb'), (IUbbb), (lie), (IIcc), (lid), (Ildd), (Ilddd), (III), (Ilia), (Illaa), (Illaa'), (Illaaa), (Illb), (Illbb), (IIIc), (IIIcc) and (IIIcc') or a derivative thereof conjugated to a polypeptide and/or a payload.
  • FIG. 1 A schematic representation of hydrolysis of compounds of the disclosure
  • n is 0. In one embodiment n is 1. In one embodiment m is 0. In one embodiment m is 1. In one embodiment p is 0. In one embodiment p is 1.
  • X is CQ-18 alkyleneC _i o
  • aryl or heteroaryl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, (4.5 alkyl, (4.5 alkoxy, -COOR 3 , -COR 3 , - CN, -CF3, -N0 2 , -S0 2 , -SO3, -NR 4 R 5 , -PO4, -(CH2-0-CH2)q-0-R 3 .
  • X is C0 5 alkyleneC5_i Q Aryl(-CH 2 CR 2 CH 2 -)p, for example
  • CQ-6 alkyleneC 4 Q Aryl such as C54 Q Aryl, in particular phenyl.
  • Z is a saturated or unsaturated branched or unbranched C ⁇ _ 2 5 alkylene chain, wherein one or more carbons (such as 1, 2, 3, 4, 5, 6, 7 or 8) are optionally independently replaced by -0-, N and the chain is optionally bears one or more (such as 1, 2, 3 or 4) oxo substituents.
  • aryl such as phenyl will be linked by a covalent bond directly to the nitrogen of the maleimide ring, except where p is 1.
  • the aryl such as phenyl bear the "Rl-Q-(Z) m " containing substituent in the ortho, meta or para position, for example meta or para such as the para position.
  • the aryl such as phenyl may be substituted with one, two, three or four substituents which are independently selected from electron donating, electron withdrawing and neutral substituents.
  • aryl, such as phenyl is substituted by one, two, three or four electron withdrawing groups.
  • the aryl, such as phenyl is substituted by one, two, three or four electron donating groups.
  • the Aryl, such as phenyl is substituted by one, two, three or four groups with neutral electronic properties. Similar substitution patterns may also be applied to heteraryls, as appropriate.
  • aryl such as phenyl is substituted with one, two, three or four substituents, for example independently selected from halogen, C ⁇ .3 alkyl, trifluoromethyl, such a chloro or fluoro, in particular one, two, three or four fluoro atoms.
  • substituents for example independently selected from halogen, C ⁇ .3 alkyl, trifluoromethyl, such a chloro or fluoro, in particular one, two, three or four fluoro atoms.
  • Molecules containing one or more fluoro atoms may be useful in imaging techniques, such as positron emission tomography.
  • aryl such as phenyl bears one substituent in the ortho, meta or para position, for example in the meta or para position of the ring connected to the maleimide.
  • aryl such as phenyl bears two substitutents, for example in the meta, para position; meta, ortho position; ortho para position; meta, meta position; or ortho, ortho position of the ring connected to the maleimide.
  • the aryl such as phenyl bears three substituents, for example in the ortho, meta and para position; ortho, meta, meta position; ortho, ortho, para position; or meta, meta, para position of the ring connected to the maleimide.
  • aryl such as phenyl has no substituents.
  • the present disclosure also extends to substituent patterns described above in relation to aryl and phenyl as applied to heteroaryl.
  • the heteroaryl is not pyridine.
  • Conjugation to a solid surface is an important aspect of the present disclosure because it allows polypetides to be attached to beads or plates, for example of synthetic material such as plastic or resin, to facilitate purification or screening, such as high-through-put screening.
  • R1 is a pay load molecule, examples of which are given below in the definition section.
  • R1 is H.
  • R1 is a solid surface.
  • R.1, Q, Z and m are defined above for compounds of formula (I), and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ .5 alkyl, C ⁇ .5 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -N0 2 , -S0 2 , -SO3, -NR 4 R5, -PO4 and -(OCH 2 CH 2 ) q -OR 3 .
  • R1, Q, Z and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group halogen, hydroxyl, Ci .5 alkyl, Ci _6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -N0 2 , -S0 2 , -SO3, -NR 4 R 5 , -PO4 and -(OCH 2 CH 2 ) q -OR 3 .
  • R.1, Q, Z and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group halogen, hydroxyl, Ci _6 alkyl, Ci .5 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -NO2, -SO2, -SO3, -NR 4 R 5 , -PO4 and -(OCH 2 CH2) q -OR 3 .
  • the maleimide molecule is in a compound of formula (Ilaaa):
  • R1, Q, and m are defined above for compounds of formula (I), the phenyl has 0, 1, 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci _6 alkyl, Ci _6 alkoxy, -COOR 3 , -COR 3 , -
  • Z' is a saturated or unsaturated branched or unbranched Ci .24 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents.
  • group RlQ(Z') m NC(0)- is in the para position. In one embodiment the group RlQ(Z') m NC(0)- is in the meta position.
  • the maleimide entity is in a molecule of formula (lib):
  • R1, Q, Z and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci .5 alkyl, Ci .5 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -NO2, -SO2, -SO3, -NR 4 R 5 , -PO4 and -(OCH 2 CH2) q -OR 3 .
  • the group RlQ(Z) m C(0)- is in the meta position as shown in the compound of formula (Il '):
  • the maleimide entity is in a molecule of formula (Ilbbb):
  • R1, Q and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ .5 alkyl, C ⁇ .5 alkoxy, -COOR 3 ,
  • Z' is a saturated or unsaturated branched or unbranched Ci .24 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents.
  • group RlQ(Z') m NC(0)- is in the para position of the phenyl ring. In on embodiment the group RlQ(Z') m NC(0)- is in the meta position of the phenyl ring.
  • the maleimide entity is in a molecule of formula (lie):
  • the maleimide entity is in a molecule of formula (lice):
  • Z' is a saturated or unsaturated branched or unbranched Ci .24 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents, and pharmaceutically acceptable salts thereof.
  • the maleimide entity is in a molecule of formula (lid):
  • Q, Z, R1, R ⁇ and m are defined above in claim 1, and the phenyl has 0, 1, 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ .5 alkyl,
  • Q, Z, R1, R ⁇ and m are defined above in claim 1, and the phenyl has 0, 1, 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ .5 alkyl, Ci _6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -N0 2 , -S0 2 , -SO3, -NR 4 R 5 , -PO4 and -
  • the maleimide entity is in a molecule of formula (Ilddd):
  • the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci _ 6 alkyl, Ci _ 6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF 3 , -N0 2 , -S0 2 , -
  • Z' is a saturated or unsaturated branched or unbranched C ⁇ _ 2 4 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents and pharmaceutically acceptable salts thereof.
  • the group RlQ(Z') m NC(0)- is in the para position of the phenyl ring. In one embodiment the group RlQ(Z') m NC(0)- is in the meta position of the phenyl ring.
  • a compound of formula lie, IIcc, lid, Ildd or a derivative thereof is provided as the E isomer.
  • a compound of formula lie, IIcc, lid, Ildd or a derivative thereof is provided as the Z isomer.
  • the maleimide molecule is in a compound of formula (Ilia):
  • R1 , Q, Z and m are defined above for compounds of formula (I), and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ _6 alkyl, C ⁇ _6 alkoxy, -COOR 3 ,
  • R1, Q, Z and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ _6 alkyl, C ⁇ _6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -N0 2 , -S0 2 , -SO3, -NR 4 R 5 , -PO4, and -(OCH 2 CH 2 ) q -OR 3 .
  • the group RlQ(Z) m - is in the meta position as shown in the compound of formula (Illaa'):
  • R1 , Q, Z and m are defined above for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, C ⁇ .5 alkyl, C ⁇ .5 alkoxy, -COOR 3 ,
  • R1 , Q, and m are defined above for compounds of formula (I), the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, (4.5 alkyl, (4.5 alkoxy, -COOR 3 , -COR 3 ,
  • Z' is a saturated or unsaturated branched or unbranched Ci .24 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents.
  • the RlQ(Z') m NH- is in the para position of the phenyl ring. In one embodiment the RlQ(Z') m NH- is in the meta position of the phenyl ring.
  • the maleimide entity is in a molecule of formula (Mb):
  • the maleimide entity is in a molecule of formula (Illbb): or isomer thereof wherein R ⁇ and RlQ(Z') m NHC(0)- are transposed,
  • Q, Z, R1 , R ⁇ and m are defined for compounds of formula (I) and Z' is a saturated or unsaturated branched or unbranched Ci .24 alkylene chain, wherein one or more carbons are optionally independently replaced by -0-, N and the chain is optionally bears one or more oxo substituents, and pharmaceutically acceptable salts thereof.
  • the maleimide entity is in a molecule of formula (IIIc): or isomer thereof wherein R ⁇ and RlQ(Z') m NHC(0)Ph- are transposed,
  • Q, Z, R1 , R ⁇ and m are defined for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci _ 6 alkyl, Ci _ 6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF 3 , -N0 2 , -S0 2 , -SO3,
  • the maleimide entity is in a molecule of formula (IIIcc):
  • Q, Z, R1 , R ⁇ and m are defined for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci _ 6 alkyl, Ci _ 6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF 3 , -N0 2 , -S0 2 , -SO3, - NR4R5, -PO4 and pharmaceutically acceptable salts thereof.
  • n, Q, Z, R1, R ⁇ and m are defined for compounds of formula (I) and the phenyl has 0, 1 , 2, 3 or 4 substituent independently selected from the group comprising halogen, hydroxyl, Ci _6 alkyl, Ci _6 alkoxy, -COOR 3 , -COR 3 , -CN, -CF3, -NO2, -SO2, -SO3, - NR4R5, -PO4 and -(OCH2CH2)q-OR 3 , and pharmaceutically acceptable salts thereof.
  • a compound of formula lie, IIcc, lid, Ildd, Ildd', Ilddd, Illb, Illbb, IIIc, IIIcc, IIIccc, Hid or a derivative thereof is provided as the E isomer.
  • a compound of formula lie, IIcc, lid, Ildd, Ildd', Ilddd, Illb, Illbb, IIIc, IIIcc, IIIccc, Hid or a derivative thereof is provided as the Z isomer.
  • R ⁇ is fluoro
  • fragment -QZ i.e. where m is 1) or -QZ'NH (where m is 1), as appropriate within the given structure, represents:
  • Q is a bond.
  • Q is a conjugation component.
  • Conjugation component is an entity that can be employed to conjugate one molecule or fragment to another molecule or fragment.
  • Q comprises or is a function group for example selected from the group comprising, tetrazine, functionalized tetrazine, NHS ester (N-hydroxy succimide ester), tetrafluorophenyl ester, and combinations thereof.
  • the Q is a polymerizable function groupd for example selected from the group comprising an alkyne, tetrazine, derivatized tetrazine, lipid, nanoparticle, dendrimer, metal chelator and combinations thereof.
  • the conjugation components Q is a click chemistry component. Examples of click chemistry components include residues the Click-matesTM collection, such as:
  • Residues as employed herein refer to the structure that is left after the relevant reaction to join the molecule to one or more other molecular fragments (components) has taken place.
  • the conjugation component is BCN.
  • conjugation component Q is biotin. In one embodiment the Q is the fragment:
  • Z is independently selected from -Ci _ 1 2 alkylene
  • -OC(0)(CH 2 CH 2 0)i_ 8 (CH2)o-lNH e.g. -OC(O)(CH 2 CH 2 O)i_ 6 (CH2)0-lNH, such as - OC(0)(CH 2 CH 2 0)2,3,4,5(CH 2 )o-lNH, more specifically -OC(0)(CH 2 CH 2 0) 4 NH.
  • Z' is are independently selected from -Ci _1 2 alkylene, -OC(0)(CH 2 CH 2 0)i _ 8 (CH 2 )o_i, for example -OC(0)(CH 2 CH 2 0)i _ 6 (CH 2 ) 0 _i, such as -OC(0)(CH 2 CH 2 0) 25 3 5 4 5 5(CH 2 )o_i, more specifically -OC(0)(CH 2 CH 2 0) 4 .
  • Y-X in molecules of formula (I) is C(0)CH2phenyl(maleimide ( succinimide) and m is 0 and Q is a bond and the pay load is linked via amide bond with the oxo group in the fragment Y-X.
  • the payload is linked via a labile bond, for example hydrazone (low pH release), disulfide, imine or similar.
  • a labile bond for example hydrazone (low pH release), disulfide, imine or similar.
  • salts can be used, for example mineral acid salts, such as hydrochlorides, hydrobromides, phosphates and sulphates, or salts of organic acids, such as acetates, propionates, malonates and benzoates.
  • mineral acid salts such as hydrochlorides, hydrobromides, phosphates and sulphates
  • organic acids such as acetates, propionates, malonates and benzoates.
  • the maleimide entity is conjugated via a native cysteine in the polypeptide.
  • the maleimide in conjugate via a cysteine engineered into the polypeptide also referred to herein as an engineered cysteine.
  • the cysteine is a solvent exposed cysteine.
  • one or more conjugation steps for example conjugation of the maleimide to the polypeptide is performed at a pH in the range 5 to 9, for example pH 5.5 to 8.6, such as 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5 or 8.6 or a combination of one or more of said pH values.
  • pH 5.5 to 8.6 such as 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5 or 8.6 or a combination of one or more of said pH values.
  • one or more conjugation steps for example conjugation of the maleimide to the polypeptide is performed at a temperature in the range about 4 to about 37°C, for example 8 to 37°C, 8 to 30°C, 8 to 25°C or 21 to 31°C, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 or 37°C or a combination of one or more said temperatures.
  • one or more conjugation steps are performed in a suitable buffer, for example a buffer selected from the group comprising phosphate buffer, citrate buffer, borate buffer, HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), MES (2-(N- morpholino)ethanesulfonic acid)), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MOPS (3-(N-morpholino)propanesulfonic acid)), such as phosphate.
  • a buffer selected from the group comprising phosphate buffer, citrate buffer, borate buffer, HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), MES (2-(N- morpholino)ethanesulfonic acid)), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MOPS (3-(N-morpholino)propanes
  • the buffer does not comprise a primary amine, for example TRIS and the like.
  • the efficiency of one or more conjugations reactions for example the maleimide conjugation to the polypeptide is 50% or greater, for example 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%.
  • the ratio of a compound of formula (I) and other formulas described herein to polypeptide in the conjugation step is 1 to 1 respectively to 5 to 1, such as 2 to 1, 3 to 1 or 4 to 1.
  • the thiol-conjugate is further reacted with a payload, nanoparticle, or solid surface by Cu(I) catalized azide-alkyne cycloaddition (CuAAC) using copper salts, reducing agents such as sodium ascorbate, and/or Cu(I) stabilizing ligands such as; 2- [4- ⁇ (bis[(l -tert-butyl- 1H- 1 ,2,3-triazol-4-yl)methyl]amino)- methyl ⁇ -lH-l,2,3-triazol-l-yl]ethyl hydrogen sulfate ( BTTES); tris[(l- benzyl- 1 H- 1 ,2, 3-triazol-4-yl)methyl] amine (TBTA) ; tris [( 1 -hydroxypropyl- lH-l,2,3-triazol-4-yl)methyl]amine (THTPA), and the like to form a triazole linkage.
  • the thiol-conjugate is further reacted with a payload
  • SPAAC strain-promoted azide-alkyne cycloaddition
  • BARAC biarylazacyclooctynone
  • DBCO dibezocyclooctyne
  • BCN bicyclo[6.1.0]nonyne
  • the thiol-conjugate is further reacted with a payload
  • a hydrolysis step employed in the method for example the hydrolysis of the a resultant succinimide is performed at a pH in the range 7 to 12, for example pH7.4 to 9, such as 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9 or 9.0 or a combination of one or more the same.
  • a buffer is employed in the hydrolysis step, for example a buffer selected from the group comprising phosphate buffer, citrate buffer, borate buffer, HEPES (4- (2-hydroxyethyl)-l-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid)), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MOPS (3-(N- morpholino)propanesulfonic acid)), such as phosphate.
  • one or more hydrolysis steps for example hydrolysis of a succinimide is performed at a temperature in the range about 4 to about 37 °C, for example 8 to 37°C, 8 to 30°C, 8 to 25°C or 21 to 31°C, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 or 37°C or a combination of one or more said temperatures.
  • one or more reactions in the present method for example the conjugation reaction, are performed in the presence of a catalyst.
  • catalysts include transition metal catalysts, such as copper, tin, inorganic oxides, such as molybdate.
  • the one or more reactions in the present method for example the conjugation reaction do not employ a catalyst.
  • hydrolysis occurs highly efficiently post-conjugation so conditions can readily be chosen such that the conjugation and hydrolysis take place sequentially in the same reaction. Indeed, this is desirable as it minimizes the number of steps.
  • conditions for downstream steps e.g., filtration, storage, buffer exchange, purification over a column
  • the hydrolysis does not employ a combination of low pH and low temperature.
  • the present disclosure also extends to the hydrolysed molecules, for example prepared or obtainable from the method.
  • the molecules are of formula (IV):
  • R6 is H or a polypeptide residue, is H or a polypeptide residue, wherein at least one of R 6 or R 7 is a polypeptide residue and the other is H.
  • the hydrolysis can occur at one of two positions as shown in scheme 1 :
  • P represents a polypeptide
  • the present disclosure extends to compounds/molecules obtained or obtainable from the method herein.
  • the molecules prepared are stable, or example physically, chemically and thermally stable.
  • Evidence of physically instability is, for example aggregation, which can be measured by routine techniques, such as size exclusion chromatography.
  • Evidence of chemical instability is, for example degradation or disintegration of the molecule, such as disconnection of the payload.
  • Evidence of thermal instability is, for example denaturing.
  • hydrolysed molecules of the present disclosure there is 20% loss or less of the payload after incubation with beta-mercaptoethanol, for example 10% loss or less, such as 5% loss or less. In one embodiment the loss occurs over a period 1 to 36 hours, such as 2 to 24 hours.
  • hydrolysed molecules of the present disclosure there is 20% loss or less of the payload after incubation with serum (for example murine serum or bovine serum), for example 10% loss or less, such as 5% loss or less. In one embodiment the loss occurs over a period of 1 to 36 hours, such as 24 hours.
  • serum for example murine serum or bovine serum
  • the reduction in potency for example as measured by IC50, upon incubation of serum, is 20% or less, for example 10% or less, such as 5% or less, more specifically 4%, 3%, 2% or 1%.
  • a Michael addition (also referred to herein as a 1,4-Michael addition) is a
  • nucleophilic addition of a carbanion or other anion to an alpha-beta unsaturated carbonyl compound is provided.
  • Alkyl as used herein refers to straight chain or branched chain alkyl, such as, without limitation, methyl, ethyl, propyl, so-propyl, butyl, and ieri-butyl. In one embodiment alkyl refers to straight chain alkyl. Alkyl is a terminal group that is to say at the end of chain. Ci_6 alkyl includes Ci, C 2 , C3, C 4 , C5 and C 6 .
  • Alkoxy as used herein refers to straight or branched chain alkoxy, for example methoxy, ethoxy, propoxy, butoxy. Alkoxy as employed herein also extends to embodiments in which the oxygen atom is located within the alkyl chain, for example -CH 2 CH 2 OCH 3 or - CH 2 OCH 3 . In one embodiment the alkoxy is linked through oxygen to the remainder of the molecule. In one embodiment the disclosure relates to straight chain alkoxy.
  • Aryl as employed herein refers to a a C5 to C35 carbocyclic system, for example a C5 to Ci 0 carbocyclic system comprising at least one aromatic ring, for example napthylene, phenyl, indene, indane, 1, 2, 3,4-tetrahydronapthylene, azulene, for example napthylene or phenyl, such as phenyl.
  • Heteroaryl is a 5.35 membered aromatic carbocylic ring or bicyclic ring system comprising one or more, (for example 1 , 2, 3 or 4) heteroatoms independently selected from O, N and S.
  • heteroaryls include: pyrrole, oxazole, thiazole, isothiazole, imidazole, pyrazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine, benzothiophene, benzofuran, or 1 , 2, 3 and 1, 2, 4 triazole.
  • a bicyclic ring system the definition of heteroaryl will be satisfied if at least one ring contains a heteroatom and at least one ring is aromatic.
  • the heteroaryl may be linked to the remainder of the molecule through a carbocyclic ring or a ring comprising a heteroatom.
  • Ci-25 alkylene chain wherein at least one carbon (for example 1 , 2 or 3 carbons, suitably 1 or 2, in particular 1) is replaced by a heteroatom selected from O, N and said chain is optionally, substituted by one or more groups oxo, groups
  • the heteroatom may replace a primary, secondary or tertiary carbon, that is CH 3 , -CH2- or a -CH- or a branched carbon group, as technically appropriate.
  • Alkylene is a linking group i.e.
  • Ci_ 2 s alkylene includes Ci, C 2 , C 3 , C 4 , C5, C 6 , C 7 , C 8 or C 9 , C 10 , Cn, C 12 , C 13 , C 14 , Ci5, Ci6, Cn, Ci8, C19, C20, C21, C22, C23, C24 and C25-
  • Co is where the "feature" is absent.
  • Halo or halogen as employed herein refers to iodo, bromo, chloro or fluoro, such as fluoro.
  • Conjugated as employed herein refers to a compound/molecule formed by joining two compounds or molecules or fragments together.
  • Hydrolysis refers to reactions with cleave rings or molecules by the addition of a water molecule.
  • Electron withdrawing group refers to a substituent that draws electrons (or at attracts electrons) from the entity to which is it attached.
  • Electron donating group refers a substitutent that gives "donates” eletrons to the entity to which it is attached.
  • a neutral group in the context of the present disclosure does not relate to charge as such but refers to electron donating or withdrawing properties. These groups have no impact on the electronic properties on the entity to which they are attached.
  • polypeptide polypeptide
  • peptide protein
  • the terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • Polypeptide as employed herein refers to a sequence of 5 or more amino acids, with or without secondary or tertiary structure comprising at least one thiol group.
  • polypeptides includes peptides, polypeptides and proteins. These are used interchangeably unless otherwise specified.
  • the polypeptide is a protein. Proteins generally contain secondary and/or tertiary structure and may be monomeric or multimeric in form.
  • the protein is an antibody as single chains or associated chains or binding fragment thereof.
  • antibody or “immunoglobulin,” as used interchangeably herein, include whole antibodies and any antigen binding fragment or single chains thereof.
  • a typical antibody comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH, VH region, or VH domain) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three or four constant domains, CHI , CH2, CH3, and CH4.
  • the Fc region includes the polypeptides comprising the constant region of an antibody excluding the first constant region immunoglobulin domain, and fragments thereof.
  • the "Fc region” refers to CH2 and CH3 and optionally all or a portion of the flexible hinge region N-terminal to these domains.
  • the term "Fc region” can refer to this region in isolation, or this region in the context of an antibody, antibody fragment, or Fc fusion protein.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as VL, VL region, or VL domain) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • VH and VL regions can be further subdivided into regions of hypervariability, termed Complementarity Determining Regions (CDR), interspersed with regions that are more conserved, termed framework regions (FW).
  • CDR Complementarity Determining Regions
  • FW framework regions
  • Each VH and VL is composed of three CDRs and four FWs, arranged from amino-terminus to carboxy-terminus in the following order: FW1 , CDR1 , FW2, CDR2, FW3, CDR3, FW4.
  • Framework regions can be designated according to their respective VH and VL regions.
  • VH-FW1 would refer to the first framework region of VH.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g. , effector cells) and the first component (C lq) of the classical complement
  • antibody means an immunoglobulin molecule or antigen binding fragment thereof that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site (also referred to as a binding site) within the variable region of the immunoglobulin molecule.
  • a target such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site (also referred to as a binding site) within the variable region of the immunoglobulin molecule.
  • antibody encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single chain antibody fragments (scFv and disulfide stabilized scFv (dsFv)), multispecific antibodies such as bispecific antibodies generated from at least two different antibodies or multispecific antibodies formed from antibody fragments (see, e.g, PCT Publications WO96/27011 , WO2007/024715WO2009018386, WO2009/080251, WO2013006544, WO2013/070565, and WO2013/096291), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen-binding fragment of an antibody, and any other modified immunoglobulin molecule comprising an antigen-binding fragment so long as the antibodies exhibit the desired biological activity.
  • antibody fragments such as Fab, Fab', F(ab')2, and Fv fragments
  • An antibody can be of any the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) (e.g. IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), or allotype (e.g., Gm, e.g., Glm(f, z, a or x), G2m(n), G3m(g, b, or c), Am, Em, and Km(l, 2 or 3)).
  • the different classes of immunoglobulins have different and well known subunit structures and three-dimensional configurations.
  • Antibodies may be derived from any mammal, including, but not limited to, humans, monkeys, pigs, horses, rabbits, dogs, cats, mice, etc., or other animals such as birds (e.g. chickens).
  • antigen-binding fragment refers to a fragment comprising antigenic determining variable regions of an intact antibody. It is known in the art that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antibody fragments include, but are not limited to Fab, Fab', F(ab')2, Fv fragments, scFvs, linear antibodies, single chain antibodies, and multispecific antibodies formed from antibody fragments.
  • the antibody used in the present invention may comprise a complete antibody molecule having full length heavy and light chains or a fragment thereof and may be, but are not limited to Fab, modified Fab, Fab', modified Fab', F(ab') 2 , Fv, single domain antibodies (e.g. VH or VL or VHH), scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies, combinations of the same and epitope-binding fragments of any of the above.
  • oligoclonal antibodies which are a predetermined mixture of distinct monoclonal antibodies. See, e.g., PCT publication WO 95/20401 ; U.S. Pat. Nos. 5,789,208 and 6,335, 163.
  • oligoclonal antibodies consist of a predetermined mixture of antibodies against one or more epitopes are generated in a single cell. More preferably oligoclonal antibodies comprise a plurality of heavy chains capable of pairing with a common light chain to generate antibodies with multiple specificities (e.g., PCT publication WO 04/009618). Oligoclonal antibodies are particularly useful when it is desired to target multiple epitopes on a single target molecule. Those skilled in the art will know or can determine what type of antibody or mixture of antibodies is applicable for an intended purpose and desired need.
  • moieties specifically contemplated for use in the present disclosure are small, engineered protein domains such as scaffold (see for example, U.S. Patent Publication Nos. 2003/0082630 and 2003/0157561).
  • Scaffolds are based upon known naturally-occurring, non-antibody domain families, specifically protein extracellular domains, which typically of small size (-100 to -300 AA) and containing a highly structured core associated with variable domains of high conformational tolerance allowing insertions, deletions or other substitutions. These variable domains can create a putative binding interface for any targeted protein.
  • the design of a generic protein scaffold consists of two major steps: (i) selection of a suitable core protein with desired features and (ii) generation of complex combinatorial libraries by mutagenizing a portion or all of the domains accepting high structural variability, display of these libraries in an appropriate format (i.e., phage, ribosome, bacterial, or yeast) and screening of the library for mutagenized scaffold having the desired binding characteristics (e.g. target specificity and/or affinity).
  • the structure of the parental scaffolds can be highly diverse and include highly structured protein domains including but not limited to, Fnlll domains (e.g., AdNectins, see, e.g., Protein Eng. Des. Sel.
  • C-type lectin domains (Tetranectins, see, e.g., WO02/48189). If desired two or more such engineered scaffold domains can be linked together, to form a multivalent binding protein.
  • the individual domains can target a single type of protein or several, depending upon the use/disease indication.
  • Virtually any molecule may be targeted by and/or incorporated into a moiety including, but not limited to, integral membrane proteins including ion channels, ion pumps, G-protein coupled receptors, structural proteins; adhesion proteins such as integrins; transporters; proteins involved in signal tranduction and lipid- anchored proteins including G proteins, enzymes such as kinases including membrane-anchored kinases, membrane-bound enzymes, proteases, lipases, phosphatases, fatty acid synthetases, digestive enzymes such as pepsin, trypsin, and chymotrypsin, lysozyme, polymerases; receptors such as hormone receptors, lymphokine receptors, monokine receptors, growth factor receptors, cytokine receptors; cytokines; and more.
  • integral membrane proteins including ion channels, ion pumps, G-protein coupled receptors, structural proteins; adhesion proteins such as integrins; transporters; proteins involved in signal tranduction and lipid-
  • a polypeptide employed in the present disclosure targets and/or incorporates all or a portion (e.g., subunits, domains, motifs or a epitope) of a growth factor, a cytokine, a cytokine-related protein, a growth factor, a receptor ligand or a receptor selected from among, for example, BMP1, BMP2, BMP3B (GDF10), BMP4, BMP6, BMP8,
  • FGF1 aFGF
  • FGF2 FGF
  • FGF3 int-2
  • FGF4 HAT
  • FGF5 FGF6
  • FGF7 KGF
  • FGF9 FGF10, FGF11 , FGF12, FGF12B, FGF14, FGF16, FGF17, FGF19, FGF20, FGF21, FGF23, FGFR, FGFR1, FGFR2, FGFR3, FGFR4, FGFRL1, FGFR6, IGF1, IGF2, IGF1R, IGF2R, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNAR1, IFNAR2, IFNB1, IFNG, IFNW1, FIL1, FIL1
  • EPSILON FIL1
  • ZETA FIL1
  • ILIA ILIA
  • IL1B IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12A, IL12B, IL13, IL14, IL15, IL16, IL17, IL17B, IL18, IL19, IL20, IL22, IL23, IL24, IL25, IL26, IL27, IL28A, IL28B, IL29, IL30, IL2RA, IL1R1, IL1R2, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL7R, IL8RA, IL8RB, IL9R, IL10RA, IL10RB, IL11RA, IL12RB1, IL12
  • a polypeptide employed in the present disclosure targets and/or incorporates all or a portion (e.g., subunits, domains, motifs or a epitope) of a chemokine, a chemokine receptor, or a chemokine-related protein selected from among, for example, CCLl(I-309), CCL2 (MCP-1/MCAF), CCL3 (MP- la), CCL4 (MIP-lb), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CCL11 (eotaxin), CCL13 (MCP-4), CCL15 (MIP-ld), CCL16 (HCC-4), CCL17 (TARC), CCL18 (PARC), CCL19 (MIP-3b), CCL20 (MIP-3a), CCL21 (SLC/exodus-2), CCL22 (MDC/STC-1), CCL23 (MPIF-1), CCL24 (MPIF-2/eotaxin- 2), CCL
  • CCR7 CKR7/EBI1
  • CCR8 CCR8/TER1/ CKR- Ll
  • CCR9 GPR-9-6
  • CCRL1 VSHK1
  • CCRL2 L-CCR
  • XCR1 GPR5/CCXCR1
  • CMKLR1, CMKOR1 RRC1
  • CX3CR1 V28
  • CXCR4 CCR10
  • HM74 IL8RA
  • IL8RB IL8RB
  • LTB4R GPR16
  • TCP10 CKLFSF2, CKLFSF3, CKLFSF4, CKLFSF5, CKLFSF6, CKLFSF7, CKLFSF8, BDNF, C5R1, CSF
  • a polypeptide employed in the present disclosure targets and/or incorporates all or a portion (e.g., subunits, domains, motifs or a epitope) of a protein selected from among, for example renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha- 1 -antitrypsin; insulin A-chain; insulin B -chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VII, factor VIIIC, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor;
  • moieties that specifically bind and/or comprises cancer antigens including, but not limited to, ALK receptor (pleiotrophin receptor), pleiotrophin, KS 1/4 pan-carcinoma antigen; ovarian carcinoma antigen (CA125); prostatic acid phosphate; prostate specific antigen (PSA); melanoma-associated antigen p97; melanoma antigen gp75; high molecular weight melanoma antigen (HMW-MAA); prostate specific membrane antigen; carcinoembryonic antigen (CEA); polymorphic epithelial mucin antigen; human milk fat globule antigen; colorectal tumor-associated antigens such as: CEA, TAG-72, CO 17- 1A, GICA 19-9, CTA-1 and LEA; Burkitt's lymphoma antigen-38.13; CD19; human B- lymphoma antigen-CD20; CD33; melanoma specific antigens such as gangli
  • FC10.2 found in embryonal carcinoma cells; gastric adenocarcinoma antigen; CO-514 (blood group Lea) found in Adenocarcinoma; NS-10 found in adenocarcinomas; CO-43 (blood group Leb); G49 found in EGF receptor of A431 cells; MH2 (blood group ALeb/Ley) found in colonic adenocarcinoma; 19.9 found in colon cancer; gastric cancer mucins; T5A7 found in myeloid cells; R24 found in melanoma; 4.2, GD3, Dl.l, OFA-1, GM2, OFA-2, GD2, and Ml :22:25:8 found in embryonal carcinoma cells and SSEA-3 and SSEA-4 found in 4 to 8- cell stage embryos; Cutaneous Tcell Lymphoma antigen; MART-1 antigen; Sialy Tn (STn) antigen; Colon cancer antigen NY-CO-45; Lung cancer antigen NY-LU-12 variant A
  • Adenocarcinoma antigen ART1 Paraneoplastic associated brain-testis-cancer antigen (onconeuronal antigen MA2; paraneoplastic neuronal antigen); Neuro-oncological ventral antigen 2 (NOVA2); Hepatocellular carcinoma antigen gene 520; TUMOR-ASSOCIATED ANTIGEN CO-029; Tumor-associated antigens MAGE-C1 (cancer/testis antigen CT7), MAGE-B1 (MAGE-XP antigen), MAGE-B2 (DAM6), MAGE-2, MAGE-4a, MAGE-4b and MAGE-X2; Cancer-Testis Antigen (NY-EOS-1) and fragments of any of the above-listed polypeptides.
  • polypeptide employed is recombinant.
  • a "recombinant" polypeptide or protein refers to a polypeptide or protein produced via recombinant DNA technology. Recombinantly produced polypeptides and proteins expressed in engineered host cells are considered isolated for the purpose of this disclosure, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.
  • the polypeptides disclosed herein can be recombinantly produced using methods known in the art. Alternatively, the proteins and peptides disclosed herein can be chemically synthesized.
  • Payload refers to a molecule or component, which is intended for "delivery" to a target region location by conjugation to the polypeptide.
  • the payload will generally be an effector molecule, for example selected from the group consisting of a toxin, for example a cytotoxin, such as a chemotherapeutic agent, a drug, a pro-drug, an enzyme, an immunomodulator, an anti-angiogenic agent, a pro- apoptotic agent, a cytokine, a hormone, an antibody or fragment thereof, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g.
  • a toxin for example a cytotoxin, such as a chemotherapeutic agent, a drug, a pro-drug, an enzyme, an immunomodulator, an anti-angiogenic agent, a pro- apoptotic agent, a cytokine, a hormone, an antibody or fragment thereof, synthetic or naturally occurring polymers, nucleic acids
  • DNA, RNA and fragments thereof e.g., an antisense molecule or a gene
  • radionuclides particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.
  • the payload is selected from the group comprising a toxin, drug, radionuclide, immunomodulator, cytokine, lymphokine, chemokine, growth factor, tumor necrosis factor, hormone, hormone antagonist, enzyme, oligonucleotide, DNA, RNA, siRNA, RNAi, microRNA, peptide nucleic acid, photoactive therapeutic agent, anti-angiogenic agent, pro-apoptotic agent, non-natural amino acid, peptide, lipid, , a polymer, carbohydrate, scaffolding molecule, fluorescent tag, visualization peptide, biotin, serum half-life extender, capture tag, chelating agent, solid support, or a combination thereof.
  • a toxin drug, radionuclide, immunomodulator, cytokine, lymphokine, chemokine, growth factor, tumor necrosis factor, hormone, hormone antagonist, enzyme, oligonucleotide, DNA, RNA, siRNA, RNAi, microRNA, peptide nucleic
  • the payload is a drug molecule (also referred to herein as a drug).
  • Examples of drug molecules for use in the present disclosure include nitrogen mustard, ethylenimine derivative, alkyl sulfonates, nitrosourea, gemcitabine, triazene, folic acid analog, anthracycline, taxane, COX-2 inhibitor, pyrimidine analog, purine analog, antibiotic, enzyme inhibitor, epipodophyllotoxin, platinum coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocortical suppressant, hormone antagonist, endostatin, taxol, camptothecin, doxorubicin, doxorubicin analog, antimetabolite, alkylating agent, antimitotic, anti-angiogenic agent, tyrosine kinase inhibitor, mTOR inhibitor, heat shock protein (HSP90) inhibitor, proteosome inhibitor, HDAC inhibitor, pro- apoptotic agent, methotrexate, CPT-1 1 , or a combination thereof, and wherein conjugation is
  • the drug is amifostine, cisplatin, dacarbazine, dactinomycin, mechlorethamine, streptozocin, cyclophosphamide, carmustine, lomustine, doxorubicin lipo, gemcitabine, daunorubicin, daunorubicin lipo, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel, docetaxel, aldesleukin, asparaginase, busulfan, carboplatin, cladribine, lO-hydroxy-7-ethyl- camptothecin (SN38), gefitinib, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, idarubicin, mesna, interferon alpha, interfer
  • alkylphosphocholines alkylphosphocholines, topoisomerase I inhibitors, taxoids and suramin.
  • toxin comprise cytotoxins or cytotoxic agents including any agent that is detrimental to (e.g. kills) cells.
  • cytotoxins or cytotoxic agents including any agent that is detrimental to (e.g. kills) cells.
  • examples include aplidin, anastrozole, azacytidine, , bortezomib, bryostatin-1 , busulfan, combrestatins, carmustine, dolastatins, epothilones, staurosporin, maytansinoids, spongistatins, rhizoxin, halichondrins, roridins, hemiasterlins, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin di
  • the drug also a cytotoxin in this instance
  • comprises an antimetabolites e.g. methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5- fluorouracil decarbazine
  • alkylating agents e.g. mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU)
  • cyclothosphamide busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin
  • carboplatin anthracyclines (e.g.
  • daunorubicin (formerly daunomycin) and doxorubicin or doxorubicin glucuronide), antibiotics (e.g. dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC), calicheamicins or
  • the drug is an auristatin (U.S. Pat. Nos. 5,635,483; 5,780,588), for example, MMAE (monomethyl auristatin E) or MMAF (monomethyl auristatin F).
  • the drug is a dolastatin or dolastatin peptidic analog or derivative. Dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al., Antimicrob. Agents and Chemother.
  • the dolastatin or auristatin drug moiety can be attached to the conjugate compound through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety. See, e.g., Intl. Publ. No. WO2002/088172, which is herein incorporated by reference in its entirety.
  • the drug is a maytansinoid.
  • the maytansinoid is N 2'- deacetyl-N 2'-(3-mercapto-l-oxopropyl)-maytansine (DM1), N 2'-deacetyl-N2'-(4-mercapto- 1 -oxopentyl)-maytansine (DM3) or N 2'-deacetyl-N 2'(4-methyl-4-mercapto-l-oxopentyl)- maytansine (DM4).
  • Maytansinoids are mitotic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S.
  • Maytansinoid drug moieties are attractive drug moieties in antibody drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical
  • Conjugates containing maytansinoids, methods of making same, and their therapeutic use are disclosed, for example, in U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP0425235B1 ; Liu et al. , Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) (described immunoconjugates comprising a maytansinoid designated DM1); and Chari et al. , Cancer Research 52: 127-131 (1992), which are herein incorporated by reference in their entireties.
  • Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Pat. No. 5,208,020. Exemplary maytansinoid drug moieties include those having a modified aromatic ring, such as: C-19-dechloro (U.S. Pat. No. 4,256,746) prepared by lithium aluminum hydride reduction of ansamytocin P2); C-20-hydroxy (or C-20-demethyl)+/-C-19- dechloro (U.S. Pat. Nos.
  • Streptomyces (U.S. Pat. Nos. 4,362,663 and 4,322,348); and 4,5-deoxy, prepared by the titanium trichloride/LAH reduction of maytansinol (U.S. Pat. No. 4,371,533).
  • Many positions on maytansine compounds are known to be useful as the linkage position, depending upon the type of link. For example, for forming an ester linkage, the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group and the C-20 position having a hydroxyl group are all suitable.
  • the drug is calicheamicin.
  • the calicheamicin family of antibiotics is capable of producing double-stranded DNA breaks at sub-picomolar concentrations.
  • conjugates of the calicheamicin family see, e.g., U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296, which are herein incorporated by reference in their entireties.
  • Structural analogues of calicheamicin that can be used include, but are not limited to, ⁇ , ⁇ 2 ⁇ , ⁇ 3 ⁇ , N-acetyl- ⁇ , PSAG and ⁇ 11 (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research
  • the drug is tubulysin.
  • Tubulysins are members of a class of natural products isolated from myxobacterial species (Sasse et al., J. Antibiot. 53:879-885 (2000)). As cytoskeleton interacting agents, tubulysins are mitotic poisons that inhibit tubulin
  • Tubulysins are extremely potent cytotoxic molecules, exceeding the cell growth inhibition of any clinically relevant traditional chemo therapeutic, e.g. , epothilones, paclitaxel, and vinblastine. Furthermore, they are potent against multidrug resistant cell lines (Domling et al , Mol. Diversity 9: 141-147 (2005)).
  • the drug is a pyrrolobenzodiazepine (PBD).
  • PBDs are relatively small molecules and some have the ability to recognize and covalently bind to specific sequences in the minor groove of DNA and thus exhibit antibiotic/antitumor activity.
  • a number of PBDs and derivatives thereof are known in the art, for example, PBD dimers (e.g., SJG-136 or SG2000), C2-unsaturated PBD dimers, pyrrolobenzodiazepine dimers bearing C2 aryl substitutions (e.g., SG2285), PBD dimer pro-drug that is activated by hydrolysis (e.g., SG2285), and polypyrrole-PBD (e.g., SG2274).
  • PBDs are further described in Intl. Publ. Nos. WO2000/012507, WO2007/039752, WO2005/110423, WO2005/085251, and
  • the toxin comprises, for example, abrin, brucine, cicutoxin, diphteria toxin, botulinum toxin, shiga toxin, endotoxin, tetanus toxin, pertussis toxin, anthrax toxin, cholera toxin, falcarinol, alpha toxin, geldanamycin, gelonin, lotaustralin, ricin, strychnine, tetrodotoxin, saponin, ribonuc lease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, Pseudomonas exotoxin, Pseudomonas endotoxin, or a combination thereof.
  • RNase ribonuc lease
  • the toxin comprises, for example, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Saponaria officinalis inhibitor, mitogellin, restrictocin, phenomycin, neomycin, tricothecenes, or a combination thereof. See, for example, Intl. Publ. No. WO1993/021232.
  • the chelating agent is DTPA, EC, DMSA, EDTA, Cy-EDTA, EDTMP, DTPA, CyDTPA, Cy2DTPA, BOPTA, DTPA-MA, DTPA-BA, DTPMP, DOTA, TRITA, TETA, DOTMA, DOTA-MA, HP-D03A, pNB-DOTA, DOTP, DOTMP, DOTEP, DOTPP, DOTBzP, DOTPME, HEDP, DTTP, an N3S triamidethiol, DADS, MAMA, DADT, an N2S4 diaminetetrathiol, an N2P2 dithiol-bisphosphine, a 6-hydrazinonicotinic acid, a propylene amine oxime, a tetraamine, a cyclam, or a combination thereof.
  • the drug is an auristatin, a tubulysin or a pyrrolobenzodiazepine
  • the auristatin is MMAE (monomethyl auristatin E) or MMAF (monomethyl auristatin F).
  • the drug is a maytansinoid, for example N 2'-deacetyl-N 2'-(3- mercapto-l-oxopropyl)-maytansine (DM1), N 2'-deacetyl-N2'-(4-mercapto-l-oxopentyl)- maytansine (DM3) or N 2'-deacetyl-N 2'(4-methyl-4-mercapto-l-oxopentyl)-maytansine (DM4).
  • DM1 N 2'-deacetyl-N 2'-(3- mercapto-l-oxopropyl)-maytansine
  • DM3 N 2'-deacetyl-N2'-(4-mercapto-l-oxopentyl)- maytansine
  • DM4 N 2'-deacetyl-N 2'(4-methyl-4-mercapto-l-oxopentyl)-may
  • radionuclides examples include 3 H, n C, 13 N, 15 0, 18 F, 32 P, 33 P, 5 S, 47 Sc, 51 Cr, 54 Mn, 57 Co, 58 Co, 59 Fe, 62 Cu, 65 Zn, 67 Cu, 67 Ga, 68 Ge, 75 Br, 75 Se, 76 Br, 77 Br, 77 As, 80m Br , 85 Sr , 89 Sr , 90 ⁇ , 95 Ru , 97 Ru , 99 Mo and 99m Tc5 103 Pd , 103m Rh , 103 Ru , 105 Rh , 105 Ru , 107 Hg , 109p d , 109 Pt , l l l Ag , l l lfo, ⁇ ln, l lSmin, 113 Sn , H5i n , H 7 Sn, 119 S b, 121m Te , 121 L 122m Te , 125m Te , 125 r ,
  • the radionuclide is selected from the group comprising or consisting of chromium ( 51 Cr), cobalt ( 57 Co), fluorine ( 18 F), gadolinium ( 153 Gd, 159 Gd), germanium ( 68 Ge), holmium ( 166 Ho), indium ( 115 In, 113 In, 112 In, in In), iodine ( 131 I, 125 I, 123 I, 121 I), lanthanum ( 140 La), lutetium ( 177 Lu), manganese ( 54 Mn), molybdenum ( 99 Mo), palladium ( 103 Pd), phosphorous ( 32 P), praseodymium ( 142 Pr), promethium ( 149 Pm), rhenium ( 186 Re,
  • radionuclide is attached to the conjugate compound of the present disclosure by a chelating agent.
  • R1 is a serum half-life extender, for example comprising albumin, albumin binding polypeptide, PAS, the ⁇ subunit of the C-terminal peptide (CTP) of human chorionic gonadotropin, polyethylene glycol (PEG), hydroxyethyl starch (HES), XTEN, albumin-binding small molecules, or a combination thereof.
  • the effector molecule is a polymer it may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero- polysaccharide.
  • Specific naturally occurring polymers include lactose, hyaluronic acid, heparan sulphate, chondroitin sulphate, alginate, cellulose amylose, dextran, glycogen or derivatives thereof.
  • the polymer is polyethylene glycol (PEG), branched PEG, polysialic acid (PSA), hydroxyalkyl starch (HAS), hydroxylethyl starch (HES), carbohydrate, polysaccharides, pullulane, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, starch, dextran, carboxymethyl-dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG) polyoxazoline, poly acryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylate, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, poly(l- hydroxymethylethylene hydroxymethylformal) (PHF), 2-methacryloyloxy
  • the polymer is polyethylene glycol.
  • the polyethylene glycol has a molecular weight range of 300 to 10,000,000, 500 to 100,000, 1000 to 50,000, 1500 to 30,000, 2,000 to 20,000 Da, 3,000 to 5,000 Da, and 4,000 to 5,000 Da. In other words,
  • the polyethylene glycol has a molecular weight of about 1,000 Da, about 1,500 Da, about 2,000 Da, about 3,000 Da, about 4,000 Da, about 5,000 Da, about 10,000 Da, or about 20,000 Da.
  • R1 or the polypeptide comprises a visualization label.
  • Visualization labels include, without limitation, a chromophore, a fluorophore, a fluorescent protein, a phosphorescent dye, a tandem dye, a particle, a hapten, an enzyme, a radioisotope, or a combination thereof.
  • the visualization label is a visualization peptide.
  • the visualization peptide enables visualization or localization of the conjugate compound in vitro, in vivo, ex vivo, or any combination thereof.
  • the visualization peptide is, for example, a biotin acceptor peptide, a lipoic acid acceptor peptide, a fluorescent protein, a cysteine-containing peptide for ligation of a biarsenical dye or for conjugating metastable technetium, a peptide for conjugating europium clathrates for fluorescence resonance energy transfer (FRET)-based proximity assays, or any combination thereof.
  • the fluorescent protein is, for example, green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), enhanced green fluorescent protein (EGFP), enhanced yellow fluorescent protein (EYFP), or any combination thereof.
  • the fluorescent protein is a phycobiliprotein or a derivative thereof.
  • Fluorescent proteins are useful for creating tandem dye labeled labeling reagents.
  • These tandem dyes comprise a fluorescent protein and a fluorophore for the purposes of obtaining a larger stokes shift where the emission spectra is farther shifted from the wavelength of the fluorescent protein's absorption spectra. This can be effective for detecting a low quantity of a target in a sample where the emitted fluorescent light is maximally optimized, in other words little to none of the emitted light is reabsorbed by the fluorescent protein.
  • the fluorescent protein and fluorophore function as an energy transfer pair where the fluorescent protein emits at the wavelength that the fluorophore absorbs at and the fluorophore then emits at a wavelength farther from the fluorescent proteins than could have been obtained with only the fluorescent protein.
  • a functional combination can be phycobiliproteins and sulforhodamine fluorophores, or sulfonated cyanine fluorophores as known in the art.
  • the fluorophore sometimes functions as the energy donor and the fluorescent protein is the energy acceptor.
  • the biarsenical dye is 4',5'-bis(l,3,2-dithioarsolan-2-yl)fluorescein
  • the biotin acceptor peptide facilitates conjugation of avidin- and streptavidin-based reagents.
  • the lipoic acid acceptor peptide facilitates conjugation of thiol-reactive probes to bound lipoic acid or direct ligation of fluorescent lipoic acid analogs.
  • R1 or the polypeptide (in particular R1) comprises a fluorescent tag.
  • the fluorescent tag comprises, for example, a fluorescein-type dye, a rhodamine-type dye, dansyl-type dye, a lissamine-type dye, a cyanine-type dye, a phycoerythrin-type dye, a Texas Red-type dye, or any combination thereof.
  • Fluorophores suitable for conjugation to the cysteine-engineered antibodies or antigen-binding fragments thereof disclosed herein include, without limitation; a pyrene (including any of the corresponding derivative compounds), an anthracene, a naphthalene, an acridine, a stilbene, an indole or benzindole, an oxazole or benzoxazole, a thiazole or benzothiazole, a 4-amino-7- nitrobenz-2-oxa-l,3-diazole (NBD), a cyanine (including any corresponding compounds), a carbocyanine (including any corresponding compounds), a carbostyryl, a porphyrin, a salicylate, an anthranilate, an azulene, a perylene, a pyridine, a quinoline, a
  • borapolyazaindacene including any corresponding compounds
  • a xanthene including any corresponding compounds
  • an oxazine including any corresponding compounds
  • a benzoxazine a carbazine (including any corresponding compounds), a phenalenone, a coumarin (including an corresponding compounds disclosed), a benzofuran (including an corresponding compounds) and benzphenalenone (including any corresponding compounds) and derivatives thereof.
  • oxazines include resorufins (including any corresponding compounds), aminooxazinones, diaminooxazines, and their benzo- substituted analogs, or any combination thereof.
  • the fluorophores include, for example, xanthene (rhodol, rhodamine, fluorescein and derivatives thereof) coumarin, cyanine, pyrene, oxazine, borapolyazaindacene, or any combination thereof.
  • fluorophores are, for example, sulfonated xanthenes, fluorinated xanthenes, sulfonated coumarins, fluorinated coumarins, sulfonated cyanines, or any combination thereof.
  • dyes sold under the tradenames and generally known as, ALEXA FLUOR®, DYLIGHT®, CY DYES®, BODIPY®, OREGON GREEN®, PACIFIC BLUE®, IRDYES®, FAM®, FITC®, and ROX®.
  • Physical properties of a fluorophore label include, but are not limited to, spectral characteristics (absorption, emission and stokes shift), fluorescence intensity, lifetime, polarization and photo-bleaching rate, or combination thereof. All of these physical properties can be used to distinguish one fluorophore from another, and thereby allow for multiplexed analysis.
  • the fluorophore has an absorption maximum at wavelengths greater than 480 nm.
  • the fluorophore absorbs at or near 488 nm to 514 nm (particularly suitable for excitation by the output of the argon-ion laser excitation source) or near 546 nm (particularly suitable for excitation by a mercury arc lamp).
  • a fluorophore can emit in the NIR (near infrared region) for tissue or whole organism applications.
  • Other desirable properties of the fluorescent label can include cell permeability and low toxicity, for example if labeling of the antibody is to be performed in a cell or an organism (e.g., a living animal).
  • R1 or the polypeptide (in particular R1) comprises a capture tag.
  • the capture tag is biotin or a His6 tag.
  • Biotin is useful because it can function in an enzyme system to further amplify a detectable signal, and it can also function as a tag to be used in affinity chromatography for isolation purposes.
  • an enzyme conjugate that has affinity for biotin can be used, such as avidin-HRP.
  • a peroxidase substrate can be added to produce a detectable signal.
  • biotin other haptens can be used, including hormones, naturally occurring and synthetic drugs, pollutants, allergens, effector molecules, growth factors, chemokines, cytokines, lymphokines, amino acids, peptides, chemical intermediates, nucleotides and the like.
  • R1 comprises an enzyme.
  • Enzymes are effective labels because amplification of the detectable signal can be obtained resulting in increased assay sensitivity.
  • the enzyme itself often does not produce a detectable response but functions to break down a substrate when it is contacted by an appropriate substrate such that the converted substrate produces a fluorescent, colorimetric or luminescent signal.
  • Enzymes amplify the detectable signal because one enzyme on a labeling reagent can result in multiple substrates being converted to a detectable signal.
  • the enzyme substrate is selected to yield the measurable product, e.g., colorimetric, fluorescent or chemiluminescence. Such substrates are extensively used in the art and are known in the art.
  • colorimetric or fluorogenic substrate and enzyme combination uses oxidoreductases such as horseradish peroxidase and a substrate such as 3,3'- diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC), which yield a distinguishing color (brown and red, respectively).
  • oxidoreductases such as horseradish peroxidase and a substrate such as 3,3'- diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC), which yield a distinguishing color (brown and red, respectively).
  • DAB 3,3'- diaminobenzidine
  • AEC 3-amino-9-ethylcarbazole
  • colorimetric oxidoreductase substrates that yield detectable products include, but are not limited to: 2,2-azino-bis(3-ethylbenzothiazoline-6- sulfonic acid) (ABTS), o- phenylenediamine (OPD), 3,3',5,5'-tetramethylbenzidine (TMB), o- dianisidine, 5 -aminosalicylic acid, 4-chloro-l -naphthol.
  • Fluorogenic substrates include, but are not limited to, homovanillic acid or 4-hydroxy-3-methoxyphenylacetic acid, reduced phenoxazines and reduced benzothiazines, including Amplex® Red reagent and its variants and reduced dihydroxanthenes, including dihydrofluoresceins and dihydrorhodamines including dihydrorhodamine 123.
  • peroxidase substrates that are tyramides represent a unique class of peroxidase substrates in that they can be intrinsically detectable before action of the enzyme but are "fixed in place” by the action of a peroxidase in the process described as tyramide signal amplification (TSA).
  • TSA tyramide signal amplification
  • the present disclosure extends to a colorimetric (and in some cases fluorogenic) substrate and enzyme combination sometimes uses a phosphatase enzyme such as an acid phosphatase, an alkaline phosphatase or a recombinant version of such a phosphatase in combination with a colorimetric substrate such as 5-bromo-6- chloro-3-indolyl phosphate (BCIP), 6-chloro-3-indolyl phosphate, 5-bromo-6-chloro-3-indolyl phosphate, p-nitrophenyl phosphate, or o-nitrophenyl phosphate or with a fluorogenic substrate such as 4- methylumbelliferyl phosphate, 6,8-difluoro-7-hydroxy-4-methylcoumarinyl phosphate (DiFMUP, U.S.
  • a phosphatase enzyme such as an acid phosphatase, an alkaline phosphatase or a recombinant version of such
  • R1 comprising a glycosidase, in particular beta- galactosidase, beta-glucuronidase and beta-glucosidase
  • a glycosidase in particular beta- galactosidase, beta-glucuronidase and beta-glucosidase
  • Appropriate colorimetric substrates include, but are not limited to, 5- bromo-4-chloro-3- indolyl beta-D-galactopyranoside (X-gal) and similar indolyl galactosides, glucosides, and glucuronides, o-nitrophenyl beta-D-galactopyranoside (ONPG) and p-nitrophenyl beta-D- galactopyranoside.
  • fluorogenic substrates include resorufin beta-D- galactopyranoside, fluorescein digalactoside (FDG), fluorescein diglucuronide and their structural variants, 4-methylumbelliferyl beta-D-galactopyranoside, carboxyumbelliferyl beta-D- galactopyranoside and fluorinated coumarin beta-D-galactopyranosides.
  • Additional enzymes include, but are not limited to, hydrolases such as cholinesterases and peptidases, oxidases such as glucose oxidase and cytochrome oxidases, and reductases for which suitable substrates are known.
  • Enzymes and their appropriate substrates that produce chemiluminescence are useful for incorporation into molecules of the present disclosure. These include, but are not limited to, natural and recombinant forms of luciferases and aequorins. Chemiluminescence- producing substrates for phosphatases, glycosidases and oxidases such as those containing stable dioxetanes, luminol, isoluminol and acridinium esters are additionally productive, wherein such heterologous moiety is a nucleic acid.
  • the nucleic acid can be selected from the group consisting of DNA, RNA, short interfering RNA (siRNA), microRNA, hairpin or nucleic acid mimetics such as peptide nucleic acids.
  • the conjugated nucleic acid is at least 10, at least 20, at least 30, at least 40, at least 50 , at least 60 at least 100, at least 200, at least 500, at least 1000, at least 5000, or more base pairs.
  • the conjugated nucleic acid can be single stranded.
  • the conjugated nucleic acid can be double stranded.
  • the conjugated nucleic acid encodes an open reading frame.
  • the open reading frame encoded by the conjugated nucleic acid corresponds to an apoptosis inducing protein, a viral protein, an enzyme, or a tumor suppressor protein.
  • Techniques for delivery of such nucleic acids to cells are known in the art.
  • Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, are referred to by their commonly accepted single-letter codes.
  • subject refers to any animal (e.g. , a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
  • subject and “patient” can be used interchangeably in reference to a human subject.
  • composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient (e.g., a conjugate compound disclosed herein) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the composition would be administered.
  • active ingredient e.g., a conjugate compound disclosed herein
  • Such composition may comprise one or more pharmaceutically acceptable excipients.
  • Such composition can be sterile.
  • an “effective amount” of a conjugate compound as disclosed herein is an amount sufficient to carry out a specifically stated purpose.
  • An “effective amount” can be determined empirically and in a routine manner, in relation to the stated purpose.
  • terapéuticaally effective amount refers to an amount of conjugate compound disclosed herein or other drug effective to "treat" a disease or disorder in a subject or mammal.
  • label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to an engineered antibody or fragment thereof disclosed herein (e.g. , a cysteine engineered antibody or fragment thereof) so as to generate a "labeled" conjugate compound.
  • the label can be detectable by itself (e.g. , radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, can catalyze chemical alteration of a substrate compound or composition that is detectable.
  • Terms such as “treating” or “treatment” or “to treat” refer to both (1) therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder and (2) prophylactic or preventative measures that prevent and/or slow the development of a targeted pathologic condition or disorder.
  • those in need of treatment include those already with the disorder; those prone to have the disorder; and those in whom the disorder is to be prevented.
  • a subject is successfully "treated” for a disease or condition, for example, cancer, according to the methods of the present disclosure if the patient shows, e.g. , total, partial, or transient remission of the disease or condition, for example, a certain type of cancer.
  • polynucleotide and “nucleic acid” are used interchangeably herein and refer to polymers of nucleotides of any length, including DNA and RNA.
  • the nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase.
  • a polynucleotide can comprise modified nucleotides, such as methylated nucleotides and their analogs.
  • vector refers to a construct, which is capable of delivering, and in some aspects, expressing, one or more gene(s) or sequence(s) of interest in a host cell.
  • vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
  • compositions Any positive embodiment or combination thereof described herein may be the basis of a negative exclusion i.e. a disclaimer.
  • compositions comprising a molecule described herein (such as hydrolysed molecules of the disclosure), in particular a pharmaceutical composition (or diagnostic composition) comprising a molecule of the present disclosure and pharmaceutical excipient, diluent or carrier.
  • composition will usually be supplied as part of a sterile, pharmaceutical composition that will normally include a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the present invention may additionally comprise a pharmaceutically- acceptable adjuvant in the context of vaccine formulation.
  • compositions for example preparation of a pharmaceutical or diagnostic composition
  • a pharmaceutical or diagnostic composition comprising adding and mixing a molecule of the present disclosure, such as hydrolysed molecule of the disclosure of the present invention together with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
  • the antibody of the disclosure may be the sole active ingredient in the pharmaceutical or diagnostic composition or may be accompanied by other active ingredients.
  • compositions suitably comprise a therapeutically effective amount of a molecule according to the disclosure.
  • therapeutically effective amount refers to an amount of a therapeutic agent needed to treat, ameliorate or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect.
  • the therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • the precise therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgment of the clinician. Generally, a therapeutically effective amount will be from 0.01 mg/kg to 50 mg/kg, for example 0.1 mg/kg to 20 mg/kg.
  • Pharmaceutical compositions may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose. The actual dose at which an molecule of the present disclosure is administered depends on the nature of the condition to be treated, for example the extent of the disease/inflammation present and on whether the molecule is being used prophylactically or to treat an existing condition.
  • compositions may be administered individually to a patient or may be administered in combination (e.g. simultaneously, sequentially or separately) with other agents, drugs or hormones.
  • the pharmaceutically acceptable carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should not be toxic.
  • Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents or pH buffering substances, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by the patient.
  • Suitable forms for administration include forms suitable for parenteral administration, e.g. by injection or infusion, for example by bolus injection or continuous infusion.
  • the product may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents, such as suspending, preservative, stabilising and/or dispersing agents.
  • the molecule of the disclosure may be in dry form, for reconstitution before use with an appropriate sterile liquid.
  • the pH of the final formulation is not similar to the value of the isoelectric point of the antibody, for example if the pH of the formulation is 7 then a pi of from 8-9 or above may be appropriate. Whilst not wishing to be bound by theory it is thought that this may ultimately provide a final formulation with improved stability, for example the antibody remains in solution.
  • compositions of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal routes. Hyposprays may also be used to administer the pharmaceutical compositions of the invention.
  • the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
  • Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue.
  • the compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • the composition comprises a polypeptide and as such, it may be susceptible to degradation in the gastrointestinal tract.
  • the composition will need to contain agents which protect the polypeptide from degradation but which release the antibody once it has been absorbed from the gastrointestinal tract.
  • the formulation is provided as a formulation for topical administrations including inhalation.
  • Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases.
  • Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
  • These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, saccharose, maltose
  • oligo- and polysaccharides e.g. dextranes
  • polyalcohols e.g. sorbitol, mannitol, xylitol
  • salts e.g. sodium chloride, calcium carbonate
  • Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns for example from 0.1 to 5 ⁇ , in particular from 1 to 5 ⁇ .
  • the particle size of the active ingredient (such as the antibody) is of primary importance.
  • propellent gases which can be used to prepare the inhalable aerosols are known in the art.
  • Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • hydrocarbons such as n-propane, n-butane or isobutane
  • halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the abovementioned propellent gases may be used on their own or in mixtures thereof.
  • Particularly suitable propellent gases are halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227.
  • halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227.
  • TG134a 1,1,1,2-tetrafluoroethane
  • TG227 1,1,2,3,3,3- heptafluoropropane
  • mixtures thereof are particularly suitable.
  • the propellent-gas -containing inhalable aerosols may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
  • the propellant-gas -containing inhalable aerosols according to the invention may contain up to 5 % by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5 % by weight, 0.01 to 3 % by weight, 0.015 to 2 % by weight, 0.1 to 2 % by weight, 0.5 to 2 % by weight or 0.5 to 1 % by weight of active ingredient.
  • topical administrations to the lung may also be by administration of a liquid solution or suspension formulation, for example employing a device such as a nebulizer, for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus(R) nebulizer connected to a Pari Master(R) compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).
  • a nebulizer for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus(R) nebulizer connected to a Pari Master(R) compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).
  • the molecules of the present disclosure can be delivered dispersed in a solvent, e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., saline or other pharmacologically acceptable solvent or a buffered solution.
  • a solvent e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., saline or other pharmacologically acceptable solvent or a buffered solution.
  • the therapeutic suspensions or solution formulations can also contain one or more excipients.
  • Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, acetate buffer and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. Solutions or suspensions can be encapsulated in liposomes or biodegradable microspheres.
  • the formulation will generally be provided in a substantially sterile form employing sterile manufacture processes.
  • This may include production and sterilization by filtration of the buffered solvent/solution used for the for the formulation, aseptic suspension of the molecule in the sterile buffered solvent solution, and dispensing of the formulation into sterile receptacles by methods familiar to those of ordinary skill in the art.
  • the present disclosure also extends to methods of treating a patient in need thereof by administering a therapeutically effective amount of a molecule according to the present disclosure or a composition, such as pharmaceutical composition comprising the same.
  • a molecule of the present disclosure or a composition comprising same for use in treatment, in particular for use of the treatment of a disease or condition described herein, such as cancer.
  • a molecule of the present disclosure or a composition comprising the same in the manufacture of a medicament for treating a condition or disease described herein, such as cancer.
  • molecules of the present invention are useful in the treatment and/or prophylaxis of a pathological condition.
  • a molecule according to the present invention for use in treatment, by administering a therapeutically effective amount thereof, for example in a pharmaceutical formulation.
  • the molec according to the disclosure is administered topically to the lungs, for example by inhalation.
  • the antibodies provided by the present invention are useful in the treatment of diseases or disorders including inflammatory diseases and disorders, immune disease and disorders, fibrotic disorders and cancers.
  • inflammatory disease or "disorder” and “immune disease or disorder” includes rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft-versus-host disease.
  • fibrotic disorder includes idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis (continuous ambulatory peritoneal dialysis), liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery.
  • IPF idiopathic pulmonary fibrosis
  • systemic sclerosis or scleroderma
  • kidney fibrosis diabetic nephropathy
  • IgA nephropathy IgA nephropathy
  • hypertension end-stage renal disease
  • peritoneal fibrosis continuous ambulatory peritoneal dialysis
  • liver cirrhosis liver cirrhos
  • cancer includes a malignant new growth that arises from epithelium, found in skin or, more commonly, the lining of body organs, for example: breast, ovary, prostate, colon, lung, kidney, pancreas, stomach, bladder or bowel. Cancers tend to infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example: to bone, liver, lung or the brain.
  • the subjects to be treated can be animals.
  • the compositions are adapted for administration to human subjects.
  • T289C monoclonal antibody
  • x-Maleimide-PEG-biotins were conjugated to mAb (comprising a T289C mutation of the Fc) in several steps.
  • mAbs were mildly reduced to generate free sulfhydryls by combining 5 mL of 1.6 mg/mL mAb solution in 10 mM PBS, pH 7.2 (8 mg mAb, 53.3 nM, 1 eq) was combined with 43 ⁇ L ⁇ of 50 mM TCEP solution in water (2.15 ⁇ , 40 eq) followed by gentle mixing at 37 °C for 1 hr.
  • Reduced mAb was transferred to a slide-a-lizer dialysis cassette (10K MWCO) and dialyzed against PBS, ImM EDTA, pH 7.2-7.8, 4°C for 24 hr with several buffer changes. Reduced mAb was oxidized to reform internal disulfides by addition of dehydroascorbic acid (21 ⁇ L ⁇ of 50 mM stock in DMSO, 1.1 ⁇ , 20 eq) followed by gentle mixing for 4 hr at room temperature.
  • dehydroascorbic acid 21 ⁇ L ⁇ of 50 mM stock in DMSO, 1.1 ⁇ , 20 eq
  • Oxidized mAb solution was adjusted to the desired pH by addition of 1M sodium phosphate (monobasic for pH 5.5, dibasic for pH 8.6, or a stock adjusted to pH 7.4) to a final phosphate concentration of 100 mM and mAb concentration of 1.3 mg/mL.
  • 1M sodium phosphate monobasic for pH 5.5, dibasic for pH 8.6, or a stock adjusted to pH 7.4
  • mAb concentration 100 mM
  • mAb concentration 1.3 mg/mL.
  • 1.15 mL of mAb solution 1.5 mg, 10 nmol, 1 eq
  • x-maleimide-PEG-biotin stock solution (2 ⁇ L ⁇ of a 10 mM stock colution in DMAc, 20 nmol, 2 eq).
  • ADC samples were analyzed using an Agilent 6520B Q-TOF mass spectrometer equipped with a RP-HPLC column (Agilent Poroshell 300SB-C3 ; 5um, 2.1 mm x 75 mm; Part# 660750-909).
  • High-performance liquid chromatography (HPLC) parameters were as follows: flow rate, 0.4 ml/min; mobile phase A was 0.1 % (v/v) formic acid in HPLC-grade H 2 0, and mobile phase B was 0.1 % (v/v) formic acid in acetonitrile.
  • the column was equilibrated in 90%A/10%B, which was also used to desalt the ADC samples, followed by elution in 40%A/60%B.
  • Mass spec data were collected for 100-3000 m/z, positive polarity, a gas temperature of 350°C, a nebulizer pressure of 48 lb/in 2 , and a capillary voltage of 5,000 V. Data were analyzed using vendor-supplied (Agilent v.B.04.00) MassHunter Qualitative Analysis software and peak intensities from deconvoluted spectra were used to derive the relative proportion of reactants and products; and reaction kinetics.
  • Example 5 Calulation of Conjugation Efficiency and Percentage Hydrolysis Calculation of Conjugation Efficiency
  • DAR drug:antibody ratio
  • Percent hydrolysis values were calculated from the peak intensities of deconvoluted mass spectra using the equation below:
  • Example 7 Analysis of x-Maleimide-PEG-biotin Conization at 1 eg Maleimide: Thiol x-Maleimide-PEG-biotin mAb conjugates were prepared for LC/MS analysis by diluting to 0.2 mg/mL with PBS pH 7.2 followed by combining 50 ⁇ of mAb solution with 5 ⁇ of TCEP (0.5 M in water). This mixture was incubated for 5 min at room temperature to reduce disulfide bonds prior to injection (15 ⁇ ) into the LC/MS. Representative data is shown in Figure 1A and IB.
  • Example 8 Analysis of x-Maleimide-PEG-biotin Conization at 0.5 eg Maleimide: Thiol x-Maleimide-PEG-biotin mAb conjugates were prepared as described above in Example 7, except that 1 eq. maleimide:mAb was used. Note that 1 equivalent x-maleimide-PEG-biotin equals 0.5 equivalent x-maleimide-PEG-biotin:thiol. 1) Alkyl maleimide-PEG-biotin (comparator) see Figure 2A
  • x-Maleimide-PEG-biotins were pre-incubated in buffer solutions of different pH to assess their stability and thiol conjugation efficiency over time. This assay indirectly monitors maleimide hydrolysis because hydrolyzed maleimides are not reactive towards thiols.
  • Antibody bearing the T289C FC mutation was reduced and oxidized as described above and adjusted to 1.5 mg/mL in PBS containing 50 mM sodium phosphate pH 7.4.
  • Example 17 Thiosuccinimide Hydrolysis Kinetics for x-Maleimide-PEG-Biotin T289C mAb Conjugates x-Maleimide-PEG-biotin mAb conjugates were incubated in buffer solutions and monitored by LC/MS over time to observe thiosuccinimide hydrolysis. First, mAb containing the T289C Fc mutation (0.75 mg, 5 nmol, 1 eq) was reacted with x-maleimide-PEG-biotin (50 nmol, 5 mL of a 10 mM stock in DMAC, 10 eq) in 577 mL PBS, pH 7.2.
  • the conjugation reaction was allowed to proceed for 5 minutes and then quenched with N-acetyl cysteine (500 nmol, 4 mL of 100 mM stock in water, 100 eq) and further incubated for 5 minutes.
  • the reaction mixture was then combined with PBS containing 0.5 mM EDTA and 1M sodium phosphate at the desired pH to achieve final concentrations of 0.65 mg/mL mAb, 100 mM phosphate, 0.5 M EDTA and 150 mM NaCl.
  • an aliquot was removed and diluted 1 :3 with 75 mM phosphate buffer pH 5.5 to obtain an initial time point sample. Samples were then further incubated at the desired conditions with aliquots removed at determined time points.
  • Thiosuccinimide hydrolysis data were also analyzed in units of molar concentration to determine kinetic constants.
  • Pseudo 1 st order rate constants were determined from the slopes of curves generated from plotting ln[maleimide] versus time and linear regression analysis. The results are shown in Figure 12.
  • Thiosuccinimide hydrolysis data were also analyzed in units of molar concentration to determine kinetic constants.
  • Pseudo 1st order rate constants were determined from the slopes of curves generated from plotting ln[maleimide] versus time and linear regression analysis. The results are shown in Figure 13.
  • Thiosuccinimide hydrolysis data were also analyzed in units of molar concentration to determine kinetic constants. Pseudo 1 st order rate constants were determined from the slopes of curves generated from plotting ln[maleimide] versus time and linear regression analysis. The results are shown in Figure 14. Summary of Thiosuccinimide Hydrolysis Kinetics for T289C mAb-PEG-biotin Conjugates
  • x-Maleimide-PEG-biotin mAb conjugates were incubated in buffer solutions containing sodium molybdate to investigate if this compound is capable of increasing thiosuccinimide hydrolysis.
  • Samples were monitored by LC/MS over time to observe thiosuccinimide hydrolysis as described above.
  • mAb containing the T289C Fc mutation 0.5 mg, 3.3 nmol, 1 eq
  • x-maleimide-PEG-biotin 50 nmol, 5 mL of a 10 mM stock in DMAC, 15 eq
  • the conjugation reaction was allowed to proceed for 5 minutes and then quenched with N-acetyl cysteine (500 nmol, 4 mL of 100 mM stock in water, 151 eq) and further incubated for 5 minutes.
  • the reaction mixture was then combined with 1M PBS containing 1M sodium molybdate at the desired pH to achieve a final concentration of 100 mM phosphate and 100 mM molybdate. After addition of molybdate, the mixture was incubated at 22 °C for 1 hr. After 1 hr, samples were diluted 1 :5 with 75 mM phosphate buffer pH 6.5 to stop hydrolysis. Samples were then sterile filtered, reduced with TCEP, and analyzed by LC/MS.
  • Biotin-mAb conjugates were incubated in aqueous buffer containing ⁇ -mercaptoethanol (BME) to challenge the thiosuccinimide linkage against deconjugation.
  • x-Maleimide-PEG- biotins were conjugated to mAb containing the T289C mutation as described above with minor modification.
  • Conjugation reactions were performed at 1 equivalent x-PEG- maleimide: thiol for 15 min at 22 °C followed immediately by dilution to 0.2 mg/mL (1.33 ⁇ mAb) with IX PBS pH 7.2 containing 0.5 mM EDTA. The N-acetyl cysteine quenching step was omitted.
  • BME BME was added to a final concentration of 1% v/v (143 mM). Samples were further incubated at 37 °C under ambient atmosphere without stirring. Aliquots were removed at various time points, sterile filtered, reduced with DTT and then analyzed by LC/MS. Percent conjugated mAb and thiosuccinimide hydrolysis were determined from peak heights of mass spectra using Equation 1 and Equation 2, respectively. Deconjugated mAb and thiosuccinimide hydrolysis data were plotted as In [concentration] vs. time (s) to obtain the psuedo-first order rate constants from the slope of the bestfit line. The results are shown in Figure 17.
  • Biotin-mAb conjugates were incubated in aqueous buffer containing ⁇ -mercaptoethanol (BME) to challenge the thiosuccinimide linkage against deconjugation.
  • BME ⁇ -mercaptoethanol
  • thiosuccinimide conjugates were subjected to a brief incubation at mildly basic conditions to faciliate thiosuccinimide hydrolysis before the stability challenge.
  • x-Maleimide-PEG-biotins were conjugated to mAb containing the T289C mutation as described above with minor modification. Conjugation reactions were performed at 1 equivalent x-PEG-maleimide:thiol for 15 min at 22 °C followed quenching with N-acetyl cysteine (100 eq rel.
  • N-alkyl maleimide Val-Cit-PAB-MMAE Maleimidocaproyl-valine-citrulline-/7-aminobenzylcarbonyl-mono- methyl-Auristatin-E (mc- ValCit-PABC-MMAE) was prepared according to the literature method with modifications.
  • N-phenyl acetyl maleimido-Val-Cit-PAB-MMAE was conjugated to mAb (comprising a T289C mutation of the Fc) in several steps.
  • mAbs were mildly reduced to generate free sulfhydryls by combining 5 mL of 1.6 mg/mL mAb solution in 10 mM PBS, pH 7.2 (8 mg mAb, 53.3 nM, 1 eq) was combined with 43 ⁇ L ⁇ of 50 mM TCEP solution in water (2.15 ⁇ , 40 eq) followed by gentle mixing at 37 °C for 1 hr.
  • Reduced mAb was transferred to a slide-a-lizer dialysis cassette (10K MWCO) and dialyzed against PBS, lmM EDTA, pH 7.2- 7.8, 4°C for 24 hr with several buffer changes. Reduced mAb was oxidized to reform internal disulfides by addition of dehydroascorbic acid (21 ⁇ of 50 mM stock in DMSO, 1.1 ⁇ , 20 eq) followed by gentle mixing for 4 hr at room temperature.
  • dehydroascorbic acid 21 ⁇ of 50 mM stock in DMSO, 1.1 ⁇ , 20 eq
  • Oxidized mAb solution (2.5 mL, 27 nmol, 1 eq) was combined 10% v/v DMSO followed by addition of N-phenyl acetyl maleimido-Val-Cit-PAB-MMAE (27 ⁇ of a 10 mM stock in DMSO, 270 nmol, 10 eq).
  • the reaction proceeded at room temperature with mixing for 1 hr and then N-acetyl cysteine (21 ⁇ of 100 mM stock in water, 2.2 ⁇ , 80 eq) was added to stop the reaction.
  • reaction mixture was then diluted 3-fold with distilled water and subjected to CHT chromatography to remove free unconjugated drug (Bio-Scale Mini Cartridge CHT Type II 40 ⁇ media column).
  • ADC was eluted with a gradient from buffer A (10 mM phoshate, pH 7.0) to buffer B (10 mM phosphate pH 7.0 containing 2M NaCl) over 25 minutes.
  • N-alkyl maleimido-Val-Cit-PAB-MMAE was conjugated to mAb (comprising a T289C mutation of the Fc) in in the same manner as N-phenyl maleimido-Val-Cit-PAB-MMAE (vide supra).
  • MMAE-mAb conjugates were incubated in aqueous buffer containing ⁇ -mercaptoethanol
  • conjugates were immediately purified by CHT chromatography to remove unconjugated drug. Samples were then subjected to brief dialysis (Slide-a-lizer casette, 10 kDa MWCO, 4 °C, 2 hr) to exchange the buffer to IX PBS, pH 7.2 containing 0.5 mM
  • Equation 1 Deconjugated mAb and thiosuccinimide hydrolysis data were plotted as ln[concentration] vs. time (s) to obtain the psuedo-first order rate
  • N-phenyl maleimide conjugates are less sensitive to mild hydrolysis than the PEG-biotin analogue, 3) Mild hydrolysis does not improve the stability of N-alkyl maleimide-MMAE conjugates, 4) N-phenyl maleimide-MMAE conjugates are very responsive to mild hydrolysis, but this step is not necessary to achieve high stability, 5) The N-phenyl maleimide spontaneously hydrolyzes significantly more than N-alkyl maleimide when subjected to identical purification processes.
  • MMAE ADCs were incubated in mouse serum to challenge the thiosuccinimide linkage towards deconjugation. MMAEs were conjugated to mAb containing the T289C mutation to produce the desired ADC as described above. After drug conjugation, ADCs were immediately purified by CHT chromatography to remove unconjugated drug. Samples were then subjected to brief dialysis (slide-a-lyzer casette, 10 kDa MWCO, 4 °C, 2 hr) to exchange the buffer to IX PBS, pH 7.2 containing 0.5 mM EDTA.
  • mAb concentrations were determined by A280 measurement (NanoDrop) and then added to normal mouse serum (Jackson Immunoresearch) to achieve a final concentration of 0.2 mg/mL (1.33 ⁇ mAb).
  • the total volume of ADC added to serum was less than 10%.
  • the ADC-serum mixture was sterile filtered and incubated at 37 °C in a sealed container without stirring. Aliquots were removed at various time points, and frozen. Conjugated and unconjugated human antibody was recovered from mouse serum by immunoprecipitation using FC-specific anti-human IgG-agarose resin (Sigma-Aldrich).
  • Figure 29A shows alkyl thiosuccinimide deconjugation and hydrolysis, pH 7.2 37°C plus BME. This data shoes that deconjugation is linked to thiosuccinimide hydrolysis. Deconjugation plateaus after maximum thiosuccinimide hydrolysis is achieved, which is consistent with BME challenge experiments.
  • MDA-MB-361 breast cancer cells with high 5T4 expression were used in these studies.
  • Cells were plated in 80 ⁇ of RPMI1640 with 10% FBS into 96-well flat-bottomed plates at 2,000 MDA-MB-361 cells/well. Cells were allowed to adhere overnight.
  • a 5X concentration of each ADC was prepared by diluting the test articles in culture medium. Twenty microliters of each test article was added to cells in duplicate such that the final dose curve range of 50 ng/mL down to 0.76 pg/mL in a stepwise 1 :4 serial dilution series.
  • a series of heterobifunctional linkers comprising both alkyl- or N-aryl based maleimides and PEG-BCN functionality were prepared.
  • the BCN group is reactive towards azides in a reaction known as "copper-free click conjugation".
  • the NHS-activated maleimide (6) was prepared in situ from (13) and used without purification. Thus, (13) (0.137 g, 0.582 mmol) was reacted with N-hydroxysuccinimide (0.074 g, 0.64 mmol) in the presence of DCC (0.144 g, 0.698 mmol) in DME (5 mL) at room temperature for 1 h. After removal of the precipitated solid (DCU) by filtration, the filtrate containing the activated ester (6) was added dropwise into a solution of endo-2 (0.2 g, 0.485 mmol) in DME (2 mL) at room temperature while stirring under N 2 . After lh, TLC and MS analyses indicated reaction completion.
  • x-Maleimide-PEG-BCNs were conjugated to mAb (comprising a T289C mutation of the Fc) in several steps.
  • mAbs were mildly reduced to generate free sulfhydryls by combining 5 mL of 1.6 mg/mL mAb solution in 10 mM PBS, pH 7.2 (8 mg mAb, 53.3 nM, 1 eq) was combined with 43 ⁇ of 50 mM TCEP solution in water (2.15 ⁇ , 40 eq) followed by gentle mixing at 37 °C for 1 hr.
  • Reduced mAb was transferred to a slide-a-lizer dialysis cassette (10K MWCO) and dialyzed against PBS, ImM EDTA, pH 7.2-7.8, 4°C for 24 hr with several buffer changes. Reduced mAb was oxidized to reform internal disulfides by addition of dehydroascorbic acid (21 ⁇ of 50 mM stock in DMSO, 1.1 ⁇ , 20 eq) followed by gentle mixing for 4 hr at room temperature. Oxidized mAb solution was adjusted tol.3 mg/mL mAb by addition of PBS.
  • mAb solution 1.5 mg, 10 nmol, 1 eq
  • x-maleimide-PEG-BCN stock solution 10 mM stock colution in DMAc, 20 nmol, 2 eq
  • the reaction mixture was briefly vortexed and incubated for 1 hr at 22 °C followed by addition of N-acetly cysteine (10 ⁇ of a 100 mM solution in water, 1 ⁇ , 100 eq) and further incubation for 15 minutes to quench unreacted maleimide. All conjugation reactions were performed at room temperature (22 °C) under ambient atmosphere.
  • x-Maleimide-PEG-BCN-mAb conjugates were incubated in buffer solutions and monitored by LC/MS over time to observe thiosuccinimide hydrolysis.
  • Conjugated T289C mAbs were diluted to 0.22 mg/mL with IX PBS containing 0.5 mM EDTA, pH 7.2 and then
  • dithiothreitol was added (0.5 M stock in water) to achieve a final concentration of 42 mM. Samples were placed into the LC/MS autosampler at 22 °C and injected periodically.
  • Thiosuccinimide hydrolysis was confirmed by addition of 18 amu to the mAb conjugate peak in the mass spectrum.
  • X-Maleimide-PEG-BCN conjugates hydrolyze in a similar trend as that observed for PEG- biotin conjugates; i.e. F-phenyl thiosuccinimide>phenyl thiosuccinimide»alkyl
  • N-phenyl-maleimide-PEG-BCN-mAb conjugate (100 ⁇ of 1.3, mg/mL solution in PBS with 0.5 mM EDTA, 0.87 nmol) was combined with AC 4 GlcNAz (1 ⁇ of 500 mM stock in DMSO, 500 nmol). The reaction solution was incubated at room temperature without stirring for 1 hr at 22 °C. For long-term reactivity studies, mAb-BCN conjugate was stored at 4 oC in PBS with 0.5 mM EDTA, pH 7.2 and aliquots were removed and reacted with AC 4 GlcNAz as described above.
  • Conjugates were analyzed by reduced glycosylated mass spectrometry and conjugation efficiency was determined using equation 1. Analysis of mAb-BCN-Ac4GlcNAz conjugates are shown in Figure 37. BCN groups reacted completely with AC 4 GlcNAz.
  • Table 29 Summary of BCN reactivity after cross-linker conjugation to mAb and storage at 4 °C
  • BCN groups show no loss of reactivity for > 21 days after conjugation and storage at 4 oC.
  • PBD-mAb conjugate linked by thioetner and triazoie N-phenyl-maleimide-PEG-BCN-T289C mAb conjugates were prepared as described above (at 1.5 mg/mL mAb) and stored at 4 °C until reaction with azido-PBD.
  • mAb solution was first combined with DMSO to achieve a final concentration of 30% v/v DMSO and 1.05 mg/mL mAb-BCN.
  • mAb-BCN/DMSO solution (1.89 mL, 13 nmol mAb, 1 eq.) was transferred to a vial and azido-PBD was added (16 ⁇ L ⁇ of 10 mM stock in DMSO, 160 nmol, 12 eq.).
  • the reaction mixture was incubated at 37 °C for one hour and then 22 °C for 18 nr.
  • the reaction mixture was first purified by dialysis (10K MWCO slide-a- lyzer cassette, IX PBS with 0.5 mM EDTA, pH 7.2, 4 °C, 18 hr) and then CHT
  • MDA-MB-361 breast cancer cells with high 5T4 expression were used in these studies.
  • Cells were plated in 80 ⁇ L of RPMI1640 with 10% FBS into 96-well flat-bottomed plates at 2,000 MDA-MB- 361 cells/well. Cells were allowed to adhere overnight.
  • a 5X concentration of each ADC was prepared by diluting the test articles in culture medium. Twenty microliters of each test article was added to cells in triplicate such that the final dose curve range of 50 ng/mL down to 0.76 pg/mL in a stepwise 1:4 serial dilution series.
  • the treated cells were cultured at 37°C/5% C0 2 for 6 days and cell viability was assessed with the CellTiter-Glo Luminescent Viability Assay from Promega. 100 ⁇ L of reconstituted CTG reagent was added each well, mildly shaken for 10 minutes at room temperature, and the absorbance of each sample at 560 nm was read using a Perkin Elmer En Vision luminometer. The percent cell viability was calculated by the following formula: (average luminescence of treated samples/average luminescence of untreated control samples) x 100. IC 50 values were determined using logistic non-linear regression analysis with GraphPad Prism software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP15782151.3A 2014-10-01 2015-10-01 Verfahren zum konjugieren eines polypeptids Active EP3200829B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462058502P 2014-10-01 2014-10-01
PCT/US2015/053397 WO2016054315A1 (en) 2014-10-01 2015-10-01 Method of conjugating a polypeptide

Publications (2)

Publication Number Publication Date
EP3200829A1 true EP3200829A1 (de) 2017-08-09
EP3200829B1 EP3200829B1 (de) 2023-12-06

Family

ID=54337383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15782151.3A Active EP3200829B1 (de) 2014-10-01 2015-10-01 Verfahren zum konjugieren eines polypeptids

Country Status (10)

Country Link
US (2) US20170304460A1 (de)
EP (1) EP3200829B1 (de)
JP (1) JP6863888B2 (de)
CN (1) CN106922129B (de)
AU (1) AU2015324924B2 (de)
BR (1) BR112017006602A2 (de)
CA (1) CA2962783A1 (de)
ES (1) ES2969960T3 (de)
RU (1) RU2715905C2 (de)
WO (1) WO2016054315A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018012524A2 (pt) 2015-12-21 2018-12-11 Bristol Myers Squibb Co anticorpos variantes para conjugação sítio-específica
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
BR112018076263A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a depleção de células
EP3571230A4 (de) 2017-01-20 2020-12-16 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd137+-zellen
CN108358995B (zh) * 2017-01-25 2021-07-06 四川大学 CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用
JP7121024B2 (ja) * 2017-02-07 2022-08-17 ハンミ ファーマシューティカルズ カンパニー リミテッド 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法
CA3047686C (en) 2017-02-08 2020-07-07 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN108864258A (zh) * 2017-05-12 2018-11-23 北京康明海慧生物科技有限公司 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
BR112021022225A2 (pt) 2019-05-06 2021-12-28 Centre Nat Rech Scient Composto, pró-droga e composição farmacêutica
EP4255447A1 (de) * 2020-12-04 2023-10-11 Dyne Therapeutics, Inc. Antikörper-oligonukleotid-komplexe und verwendungen davon
WO2024102603A1 (en) * 2022-11-07 2024-05-16 Merck Sharp & Dohme Llc Bisecting-glycan bridged conjugation for producing glycoprotein conjugates

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (de) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotikum C-15003 PHO und seine Herstellung
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP1231268B1 (de) 1994-01-31 2005-07-27 Trustees Of Boston University Bibliotheken aus Polyklonalen Antikörpern
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ526312A (en) 2000-12-13 2004-11-26 Borean Pharma As Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2003253048A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengellschaft Fur Kombinatorische Chemie Tubulysin conjugates
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
SI2270010T1 (sl) 2004-03-01 2012-05-31 Spirogen Ltd hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
PT1879901E (pt) 2005-04-21 2010-03-29 Spirogen Ltd Pirrolobenzodiazepinas
EP2495257A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
CN101309933A (zh) * 2005-09-07 2008-11-19 米迪缪尼有限公司 毒素偶联的Eph受体抗体
WO2007039752A1 (en) 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
EP2069401A4 (de) 2007-07-31 2011-02-23 Medimmune Llc Multispezifische epitop-bindende proteine und ihre verwendung
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
EP2729488A4 (de) 2011-07-06 2015-01-14 Medimmune Llc Verfahren zur herstellung multimerer polypeptide
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP2794905B1 (de) 2011-12-20 2020-04-01 MedImmune, LLC Modifizierte polypeptide für bispezifische antikörpergerüste
US10010623B2 (en) * 2012-02-16 2018-07-03 Ucl Business Plc Lysosome-cleavable linker
KR20230113821A (ko) * 2012-05-15 2023-08-01 씨젠 인크. 자가-안정화 링커 접합체
CN103288957B (zh) * 2012-12-21 2015-01-28 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
CN103333246B (zh) * 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2016054315A1 *

Also Published As

Publication number Publication date
CA2962783A1 (en) 2016-04-07
JP6863888B2 (ja) 2021-04-21
AU2015324924B2 (en) 2021-07-01
EP3200829B1 (de) 2023-12-06
US20220160882A1 (en) 2022-05-26
BR112017006602A2 (pt) 2017-12-19
CN106922129B (zh) 2024-02-20
US20170304460A1 (en) 2017-10-26
AU2015324924A1 (en) 2017-05-18
WO2016054315A1 (en) 2016-04-07
JP2017535526A (ja) 2017-11-30
RU2017114343A3 (de) 2019-04-05
RU2715905C2 (ru) 2020-03-04
CN106922129A (zh) 2017-07-04
RU2017114343A (ru) 2018-11-07
ES2969960T3 (es) 2024-05-23

Similar Documents

Publication Publication Date Title
US20220160882A1 (en) Method of conjugating a polypeptide
US20230321267A1 (en) Method And Molecules
RU2580038C2 (ru) Мультиспецифические антитела, аналоги антител, композиции и способы
JP2020184996A (ja) 多特異性抗原結合タンパク質
WO2019104075A1 (en) Trispecific binding molecules against tumor-associated antigens and uses thereof
JP2017512486A (ja) システイン操作抗体を含むコンジュゲート化合物
AU2017212484B2 (en) Methods for preparing antibodies with a defined glycosylation pattern
US20220371973A1 (en) Method and Molecules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242576

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230726

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230907

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015086833

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1242576

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240307

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240306

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1637787

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231206

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2969960

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240306

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240406

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240408

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240408

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT